Based on the forecasts for 2009 to 2011, the share is traded at a price/earnings (P/E) ratio of 23, 20 and 16 respectively.
The market, the injectable body contouring product line Macrolane, money and milestone payments are the reason that Q-Med is positioned for continued growth, HQ Bank said in a recent note to customers.
The shares in Q-Med had gained 2.68% to SEK45.90 by 17:03 CET on Wednesday on the OMX Nordic Exchange in Stockholm.
(EUR1 = SEK10.2)
Comments on this story may be sent to nbr.feedback@nordicbusinessreport.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index